Patient Square Capital LP Increases Stock Position in Astria Therapeutics, Inc. (NASDAQ:ATXS)

Patient Square Capital LP increased its holdings in shares of Astria Therapeutics, Inc. (NASDAQ:ATXS - Free Report) by 166.5% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 105,057 shares of the biotechnology company's stock after purchasing an additional 65,635 shares during the quarter. Astria Therapeutics makes up approximately 0.4% of Patient Square Capital LP's portfolio, making the stock its 20th biggest position. Patient Square Capital LP owned approximately 0.19% of Astria Therapeutics worth $939,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in ATXS. Barclays PLC grew its holdings in Astria Therapeutics by 70.5% during the third quarter. Barclays PLC now owns 92,651 shares of the biotechnology company's stock worth $1,020,000 after acquiring an additional 38,321 shares during the period. JPMorgan Chase & Co. grew its holdings in Astria Therapeutics by 101.7% during the third quarter. JPMorgan Chase & Co. now owns 39,144 shares of the biotechnology company's stock worth $431,000 after acquiring an additional 19,735 shares during the period. SG Americas Securities LLC grew its holdings in Astria Therapeutics by 51.3% during the fourth quarter. SG Americas Securities LLC now owns 21,296 shares of the biotechnology company's stock worth $190,000 after acquiring an additional 7,218 shares during the period. China Universal Asset Management Co. Ltd. acquired a new position in Astria Therapeutics during the fourth quarter worth $107,000. Finally, Rhumbline Advisers grew its holdings in Astria Therapeutics by 2.3% during the fourth quarter. Rhumbline Advisers now owns 62,163 shares of the biotechnology company's stock worth $556,000 after acquiring an additional 1,381 shares during the period. Hedge funds and other institutional investors own 98.98% of the company's stock.

Analyst Ratings Changes

ATXS has been the topic of several research reports. JMP Securities initiated coverage on Astria Therapeutics in a report on Friday, January 31st. They issued an "outperform" rating and a $26.00 target price on the stock. Cantor Fitzgerald reiterated an "overweight" rating and issued a $47.00 target price on shares of Astria Therapeutics in a research note on Wednesday, May 14th. Wedbush reiterated an "outperform" rating and issued a $28.00 price target (up from $27.00) on shares of Astria Therapeutics in a report on Wednesday, March 12th. HC Wainwright restated a "buy" rating and set a $16.00 price objective on shares of Astria Therapeutics in a research note on Tuesday, March 11th. Finally, Citizens Jmp upgraded Astria Therapeutics to a "strong-buy" rating in a research report on Friday, January 31st. Six research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of "Buy" and an average price target of $30.00.

Astria Therapeutics Stock Up 4.3%

Shares of ATXS traded up $0.17 during midday trading on Monday, hitting $4.13. The company's stock had a trading volume of 76,989 shares, compared to its average volume of 365,939. The stock has a market capitalization of $233.07 million, a price-to-earnings ratio of -1.95 and a beta of 0.45. Astria Therapeutics, Inc. has a one year low of $3.56 and a one year high of $12.92. The company's fifty day simple moving average is $5.01 and its two-hundred day simple moving average is $7.34.

Astria Therapeutics (NASDAQ:ATXS - Get Free Report) last announced its quarterly earnings data on Tuesday, May 13th. The biotechnology company reported ($0.58) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.48) by ($0.10). On average, research analysts predict that Astria Therapeutics, Inc. will post -1.65 earnings per share for the current year.

About Astria Therapeutics

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.